HAMBURG, Germany, Aug. 1, 2008 (PRIME NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC) will report its financial results for the first half of 2008 on Wednesday, August 6, 2008.
The Company is going to hold a conference call to discuss the results:
Conference call details:
Date: Wednesday, August 6, 2008
Time: 02.00 p.m. CET
01.00 p.m. BST
08.00 a.m. U.S. time (East Coast)
Conference call numbers:
Europe: +49.(0)69.5007 1305 (Germany)
+44.(0)20.7806 1950 (UK)
US: +1.718.354 1385
Pass Code: 8300274
Webcast: www.evotec.com
A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialing +49.(0)69.22222 0418 (Germany) or +44.(0)20.7806 1970 (UK) and in the U.S. by +1.718.354 1112. The access code is 8300274#. The on-demand version of the webcast will be available on our website: www.evotec.com - Investors - Financial Reports.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programs and through research collaborations, it is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries. In proprietary projects, Evotec specializes in finding new treatments for diseases of the Central Nervous System. Evotec has three programs in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation. Evotec's proprietary preclinical research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Evotec has worldwide collaboration and license agreements with Pfizer to research, develop and commercialize small molecule vanilloid receptor (VR1) antagonists. For additional information please go to www.evotec.com